Login Register Cart 0
Generic placeholder image

Current Molecular Medicine

Editor-in-Chief

ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Resveratrol-Exemestane Beneficial Regimen to Overcome the Complications over Existing Therapies for the Management of Breast Cancer

Author(s): Simranjeet Kaur and Dilpreet Singh*

Volume 24, Issue 2, 2024

Published on: 10 April, 2023

Page: [151 - 152] Pages: 2

DOI: 10.2174/1566524023666230314104442

Price: $65

Next »
[1]
Mathur P, Sathishkumar K, Chaturvedi M, et al. Cancer statistics, 2020: Report from national cancer registry programme, India. JCO Glob Oncol 2020; 6(6): 1063-75.
[http://dx.doi.org/10.1200/GO.20.00122] [PMID: 32673076]
[2]
Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: Current and emerging role. Ther Adv Med Oncol 2022; 14: 1-25.
[http://dx.doi.org/10.1177/17588359221113694] [PMID: 35923930]
[3]
Gupta P, Neupane YR, Parvez S, Kohli K, Sultana Y. Combinatorial chemosensitive nanomedicine approach for the treatment of breast cancer. Curr Mol Med 2023; 23: 1-13.
[http://dx.doi.org/10.2174/1566524023666220819122948] [PMID: 35986537]
[4]
Bradley R, Braybrooke J, Gray R, et al. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022; 23(3): 382-92.
[http://dx.doi.org/10.1016/S1470-2045(21)00758-0] [PMID: 35123662]
[5]
Xu L, Jiang W, Li W, et al. Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis. Exp Ther Med 2022; 24(3): 575.
[http://dx.doi.org/10.3892/etm.2022.11512] [PMID: 35949321]
[6]
Chaturvedi S, Garg A. A comprehensive review on novel delivery approaches for exemestane. J Drug Deliv Sci Technol 2022; 75: 103655.
[http://dx.doi.org/10.1016/j.jddst.2022.103655]
[7]
Ren B, Kwah MXY, Liu C, et al. Resveratrol for cancer therapy: Challenges and future perspectives. Cancer Lett 2021; 515: 63-72.
[http://dx.doi.org/10.1016/j.canlet.2021.05.001] [PMID: 34052324]
[8]
El-Nashar HAS, Aly SH, Ahmadi A, El-Shazly M. The impact of polyphenolics in the management of breast cancer: Mechanistic aspects and recent patents. Recent Patents Anticancer Drug Discov 2022; 17(4): 358-79.
[http://dx.doi.org/10.2174/1574892816666211213090623]
[9]
Amini P, Moazamiyanfar R, Dakkali MS, et al. Resveratrol in cancer therapy; from stimulation of genomic stability to adjuvant cancer therapy; A comprehensive review. Curr Top Med Chem 2022; 22: 1-20.
[http://dx.doi.org/10.2174/1568026623666221014152759] [PMID: 36239730]
[10]
Elzoghby AO, El-Lakany SA, Helmy MW, Abu-Serie MM, Elgindy NA. Shell-crosslinked zein nanocapsules for oral codelivery of exemestane and resveratrol in breast cancer therapy. Nanomedicine 2017; 12(24): 2785-805.
[http://dx.doi.org/10.2217/nnm-2017-0247] [PMID: 29094642]
[11]
Singh A, Neupane YR, Shafi S, Mangla B, Kohli K. PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: In vitro and in vivo assessment. J Mol Liq 2020; 303: 112649.
[http://dx.doi.org/10.1016/j.molliq.2020.112649]
[12]
Singh A, Neupane YR, Mangla B, Shafi S, Kohli K. PEGylated nanoliposomes potentiated oral combination therapy for effective cancer treatment. Curr Drug Deliv 2020; 17(9): 728-35.
[http://dx.doi.org/10.2174/1567201817666200724170708] [PMID: 32713341]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy